Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Lung cancer is the leading cause of malignancy-related death in the United States and the
second most common cancer diagnosis worldwide. In the last two decades, lung cancer …

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following
molecular profiling has dramatically changed the way advanced adenocarcinoma is treated …

Introduction: Driver molecular aberrations, such as EGFR and BRAF mutations, ALK and
ROS1 rearrangements, play an important role in the oncogenesis of non-small-cell lung …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver
mutations, which play an important role in carcinogenesis and cancer progression …

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy
and in some cases lower toxicity than conventional treatment. Although targeted …

Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …